A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer.
暂无分享,去创建一个
[1] U. Studer,et al. Abstract 2691: A randomized Phase III study comparing the efficacy of Bacillus Calmette Guérin strain Tice versus Connaught for immunotherapy of non-muscle invasive bladder cancer , 2012 .
[2] M. Babjuk,et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. , 2011, European urology.
[3] H. Herr,et al. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. , 2008, The Journal of urology.
[4] R. Sylvester,et al. Prognostic Factors in Non–Muscle-Invasive Bladder Tumors: I. Clinical Prognostic Factors: A Review of the Experience of the EORTC Genito-Urinary Group II. Biologic Prognostic Markers , 2007 .
[5] P. Malmström,et al. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin‐C and bacillus Calmette‐Guérin in patients with high‐risk bladder cancer , 2007, BJU international.
[6] D. Margel,et al. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy. , 2007, Urology.
[7] I. Yano,et al. Bacillus calmette-guerin Tokyo172 substrain for superficial bladder cancer: characterization and antitumor effect. , 2005, The Journal of urology.
[8] H. Akaza,et al. A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. , 2003, Japanese journal of clinical oncology.
[9] D. Lamm,et al. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.
[10] J. Patard,et al. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. , 2001, Urology.
[11] D. Lamm,et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.
[12] M. Behr,et al. A historical and molecular phylogeny of BCG strains. , 1999, Vaccine.
[13] K. Tozawa,et al. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer. , 1996, The Journal of urology.
[14] C. Leclerc,et al. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains , 1996, Infection and immunity.
[15] H. Akaza,et al. Bacillus calmette—Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four‐year results , 1995 .
[16] Michael Cookson,et al. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. , 1992, The Journal of urology.
[17] D. Lamm,et al. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. , 1989, The Journal of urology.